2023 World Conference on Lung Cancer (Posters)-P1.25. Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing

P1.25. Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing - PDF(Slides)

Back to course

Pdf Summary

A blood test has been developed and validated that can assess the risk of recurrence in patients with stage IA/IB non-small cell lung cancer (NSCLC). The test, called the Risk of Recurrence (ROR) blood test, was combined with the pathological grading system for invasive adenocarcinoma to refine patient recurrence risk prediction. The development and validation of the ROR test involved pre-surgery serum samples from patients at New York University Langone Health (NYU) and Rush University Medical Center (RUMC).<br /><br />The results showed that the ROR test is an independent predictor of time to recurrence and can further refine patient recurrence risk when combined with pathological grading. The test is able to evaluate the risk of recurrence for patients with resectable stage IA/IB NSCLC. The study found that the ROR test has a high predictive accuracy with a Harrell's C-index of 0.803 and an AUC at 3 years of 0.846.<br /><br />The study also identified top biological pathways associated with the ROR test, including complement activation, acute phase response, and immune response. These pathways highlight the role of the immune system in lung cancer recurrence.<br /><br />The use of the ROR test in clinical practice could help physicians identify patients at high risk of recurrence following surgery and guide more aggressive treatment or surveillance strategies. The combination of the ROR test and the adenocarcinoma grading system provides a more comprehensive approach to assessing recurrence risk in stage IA/IB NSCLC patients.<br /><br />Overall, the study demonstrates the potential of blood-based testing in improving the assessment of recurrence risk in early-stage NSCLC patients and personalizing treatment plans for better outcomes.

Asset Subtitle

Harvey Pass

Meta Tag

Speaker Harvey Pass

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

blood test

recurrence risk

stage IA/IB

non-small cell lung cancer

Risk of Recurrence

ROR blood test

pathological grading system

invasive adenocarcinoma

predictive accuracy

biological pathways